Clinical Topics

Articles

Adults in their 30s and 40s who had high BMI in adolescence were at highest risk for type 2 diabetes and early MI, regardless of adult BMI, after 24 years of follow-up, a new study finds.  


 Elevated BMI in Adolescence Increases Risk for Diabetes, Stroke in Young Adulthood, Regardless of Adult BMI 

A new study found that patients with severe obesity who had even one discussion about bariatric surgery with a clinician were more likely to lose weight but that the discussions are infrequent. 

Conversations about Bariatric Surgery May Lead to Weight Loss, Even Without the Surgery

A new study challenges traditional criteria for patient selection for metabolic surgery, demonstrating significant weight loss and disease remission for those with BMI of 30-35.  

Study Shows Benefits of Bariatric Surgery for Mild-to-Moderate Obesity 

Semaglutide 2.4 mg is the first drug approved for chronic weight management since 2014 and the first once-weekly GLP-1 receptor agonist to be approved for that purpose. 

FDA Approves Semaglutide 2.4 mg for Chronic Weight Management in Obesity, Overweight 

UK investigators found guideline-recommended post-specialist care deficient, including low levels of nutrition monitoring and widely variable prescription of dietary supplements.  

Post-bariatric Surgery Follow-up Found Inadequate, Putting Patients at Risk 

Results of this large study also suggest women with high pericardial fat volume are at greater risk for HF than men, findings that have implications for stratifying prevention and treatment. 

Pericardial Fat Increases Risk for HF, Especially HFpEF 

Dr Ethan Lazarus has practiced full-time obesity medicine since 2004. He has served on the Board of the Obesity Medicine Association since 2013, and also serves as the association’s delegate in the American Medical Association, where he played a pivotal role in the AMA’s historic decision to recognize obesity as a disease. Dr Lazarus is a highly sought-after speaker on a national level and has provided CME lectures at OMA, AMA, AAPA, OAC, TOS, Dannemiller, and many other organizations. His areas of expertise include current concepts in obesity medicine, practical pharmacotherapy, pre-packaged treatment plans, nutrition, and more.

Health care providers need to be conscious of the environment they create for patients with obesity or overweight, obesity medicine expert Ethan Lazarus, MD, explains. 

Practical Strategies for Creating Health Care Environments That Welcome Patients of all Shapes and Sizes

New topline data from the global SURPASS-4 trial shows treatment with investigational agent tirzepatide led to superior reductions in A1c and body weight vs insulin glargine.  

SURPASS-4: Tirzepatide Reduces A1c, Weight vs Glargine in Patients with T2D, High CV Risk 

The links between obesity and cardiovascular disease are many, including direct cause and effect. Click through the 10-slide summary of a new AHA statement for a first look. 

AHA Statement on Obesity and CVD: 10 Key Points, to Start 

ACC.21: High rates of obesity, hypertension, and hyperlipidemia found in Black women in their 20s and 30s are of significant concern, says the author of a study to be presented at the ACC meeting. 